Fenton reaction-based chemodynamic therapy (CDT) has emerged as a promising strategy for cancer treatment. However, its efficacy is fundamentally constrained by the limited efficiency of the Fenton reaction and a lack of tumor-selective control. To address these challenges, we develop an intelligent DNAzyme-metal-tannic acid (DzMT) nanoplatform that enables miRNA-regulated intratumoral Fenton reactions for cell-selective imaging-guided CDT. The DzMT system is constructed via coordinated self-assembly of a miRNA-activatable self-blocked DNAzyme, metal ions (Fe3+, Fe2+, and Mn2+), and tannic acid. Upon cellular uptake, the DzMT nanoplatform disassembles under acidic conditions, inducing the efficient release of therapeutic payloads. The liberated DNAzyme is activated by tumor-overexpressed oncogenic miRNAs to produce a strong fluorescence signal for selective cancer imaging. Concurrently, Mn2+ serves as a cofactor to activate the unblocked DNAzyme, leading to the cleavage of catalase mRNA. This miRNA-directed gene silencing inhibits H2O2 consumption and consequently induces substantial intracellular H2O2 accumulation. Fe2+ then catalyzes the accumulated H2O2 into highly toxic •OH and Fe3+ via the Fenton reaction. Meanwhile, the coreleased tannic acid reduces Fe3+ back to Fe2+, establishing a self-sustaining autocatalytic Fenton cycle that drives continuous •OH generation to eradicate cancer cells. This autocatalytic circuit is autonomously governed by tumor-specific miRNAs, making potent cytotoxicity being restricted to malignant cells while sparing normal tissues. Both in vitro and in vivo evaluations demonstrate high-contrast tumor imaging and effective suppression of tumor growth. This research introduces a class of tumor-specific CDT that transcends conventional material design by leveraging intrinsic biological intelligence for precise and personalized anticancer therapy.
Wang et al. (Wed,) studied this question.